Quantum Cyber (QUCY) H1 2024 earnings summary

Executive summary

• Revenue grew 4% year-over-year in the first half of 2024, with a 32% reduction in loss from operations and a 26% decrease in net loss, reflecting cost reduction efforts.

• Key clinical studies (ColoFuture and eAArly DETECT) showed high sensitivity for colorectal cancer (CRC) and advanced adenomas, with up to 97% sensitivity for CRC and 100% detection of high-grade dysplasia in advanced lesions.

• Strategic focus for late 2024 and 2025 includes expanding ColoAlertⓇ in Europe, developing next-generation CRC screening, and launching a 2,000-patient U.S. study (eAArly DETECT 2) to support FDA breakthrough device designation.

• Operational restructuring and cost reductions were implemented, primarily through reduced personnel and consulting expenses.

Financial highlights

• Six-month revenue reached $520,773, up from $499,049 in the prior year period.

• Product margin improved to 61% from 58% year-over-year.

• Total operating expenses decreased to $10.1M from $14.7M, with loss from operations narrowing to $9.8M from $14.4M.

• Net loss for the period was $11.0M, compared to $14.8M in the same period last year.

• Basic and diluted loss per share was $0.49, compared to $1.00 year-over-year.

Outlook and guidance

• Focused on maximizing shareholder value through targeted initiatives: ColoAlertⓇ growth in Europe, next-gen CRC screening, and U.S. clinical study for FDA submission.

• eAArly DETECT 2 study to enroll 2,000 average-risk U.S. patients, with results expected in the second half of 2025.

• Positive FDA feedback received for breakthrough device designation, with a request to expand clinical data.